Corneal Neurotization as a Treatment for Neurotrophic Keratopathy

Sponsor
Stanford University (Other)
Overall Status
Terminated
CT.gov ID
NCT05809245
Collaborator
(none)
4
1
1
23
0.2

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the efficacy of sural nerve transfer and cadaveric nerve graft to re-establish corneal sensation in patients with neurotrophic keratopathy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Corneal neurotization
N/A

Detailed Description

Corneal anesthesia, which can lead to visually devastating outcomes from ulceration, perforation, and scarring, can be recalcitrant to both medical and surgical treatment[1-3]. Neurotization is a revolutionary technique reported to restore corneal sensation in neurotrophic keratopathy[4-6]. Prior techniques described include direct neurotization with contralateral supraorbital and supratrochlear nerves accessed via a bicoronal incision of the scalp over the forehead[5]; nerve grafting with contralateral supratrochlear nerves accessed via a medial upper eyelid incision[6]; and sural nerve grafting to contralateral supratrochlear nerves accessed via a transverse incision over the medial upper eyelid[4]. Despite the challenges associated with these techniques (needing to subcutaneously tunnel the nerve graft over the nasal bridge or requiring a large bicoronal incision), these techniques all demonstrated efficacy in direct neurotization to improve corneal sensation in these patients.

The investigators aim to assess the efficacy of this innovative surgical technique involving coaptation of the sural nerve or cadaveric nerve allograft to an intact sensory branch of the trigeminal nerve to restore corneal sensation. The investigators have previously described the anatomic feasibility of using the infraorbital nerve using a cadaveric model, of which the results were presented at the American Society of Ophthalmic Plastic and Reconstructive Society Fall meeting in 2017. Utilization of the infraorbital nerve provides advantages over existing techniques due to ease of access via a cosmetically favorable incision, large caliber with increased ability to create a perineural window, relatively short and direct tunnel with possibly more rapid neurotization, and absence of complex surrounding anatomical structures. Others have previously describe success using the contralateral and ipsilateral supraorbital nerve and supratrochlear nerve.

Study Design

Study Type:
Interventional
Actual Enrollment :
4 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Corneal Neurotization Via Sural Nerve Transfer or Cadaveric Nerve Graft for Neurotrophic Keratopathy
Actual Study Start Date :
Mar 15, 2018
Actual Primary Completion Date :
Feb 12, 2020
Actual Study Completion Date :
Feb 12, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Corneal neurotization

Patients will undergo the corneal neurotization as described in the protocol. Their pre and post-procedure corneal sensation will be measured as a primary outcome measure. Secondary outcome measures will include visual acuity, corneal opacity, NEI VFQ, and confocal microscopy.

Procedure: Corneal neurotization
Autologous sural nerve will be harvested or cadaveric nerve graft will be coapted to an intact sensory branch of the trigeminal nerve. The nerve will be separated into fascicles which will be tunneled under the conjunctiva around the cornea near the limbus.

Outcome Measures

Primary Outcome Measures

  1. Corneal sensation [Baseline (pre-operative) to 12 months postoperatively]

    Corneal sensation will be measured via Cochet Bonnet esthesiometry

Secondary Outcome Measures

  1. Visual acuity [Baseline (pre-operative) to 12 months postoperatively]

    Measurement using Snellen eye chart

  2. Corneal opacity [Baseline (pre-operative) to 12 months postoperatively]

    Measured based on grade 0-4 based on degree of opacity.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with neurotrophic cornea
Exclusion Criteria:
  • Patients with history of penetrating keratoplasty

Contacts and Locations

Locations

Site City State Country Postal Code
1 Andrea Kossler Palo Alto California United States 94303

Sponsors and Collaborators

  • Stanford University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Andrea L Kossler, Director, Oculoplastic Surgery & Orbital Oncology Assistant Professor of Ophthalmology, Stanford University
ClinicalTrials.gov Identifier:
NCT05809245
Other Study ID Numbers:
  • 43284
First Posted:
Apr 12, 2023
Last Update Posted:
Apr 12, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Andrea L Kossler, Director, Oculoplastic Surgery & Orbital Oncology Assistant Professor of Ophthalmology, Stanford University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2023